Pricing Log in Create free account
Friday 6 November 2026 Export NXGL’s income statement to Excel — free account

NexGel, Inc.

NXGL Healthcare Medical Instruments & Supplies

NexGel, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $11.4 million, up 31.5% from fiscal 2024.

Revenue
+27.8%
EPS
−344.4%
Free cash flow
−432.3%
Total debt
+353.8%

Quarter to June 2026, against a year earlier

3.60 0.52 −12.62%
Market cap
$12.7M
P/E
0.0×
Fwd P/E
−0.2×
Dividend yield
—
F-score
5/9
Altman Z
−1.25
Beneish M
−3.41
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 0.04
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell 1 — — — — 1 4 — — — — —
Insider Ownership 6.81%

Capital & Financial Ratios $m

Size
Market Cap 12.65
Revenue ttm 12.07
Net income ttm (6.05)
Free cash flow ttm (3.34)
Net debt Q 1.99
Valuation
P/E 0.00
Forward P/E (0.19) (negative: loss-making)
Price / sales 0.15
Forward P/S Powerpack
Price / FCF 0.00
Price / book 0.32
Financial health
Current ratio Q 0.43 (below 1: weak)
Debt / equity Q 0.68
Interest coverage Q (22.81)
Growth
Revenue growth Q +27.81% (above 0%: growing)
Operating income growth Q −293.87% (below 0%: shrinking)
EPS, this year −147.37% (below 0%: weak)
EPS, next year A +76.60% (at or above 15%: strong)
Revenue, next year A +38.25% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A +49.14% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 0.3×, against a ten-year median of 1.4×; over the ten years it ranged from −4.7× in 2022 to 3.9× in 2024.
P/S against its own 10 years 1.23%
10-year low 10-year high
P/B against its own 10 years 1.23%
10-year low 10-year high
EV/Sales against its own 10 years 6.02%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 3 2 1 2
Receivables 1 1 1 1
Inventory 1 2 2 2
Other — — — —
5 5 4 6
2023 2024 2025 Q'26
Payables 1 1 1 4
ST’ Debt — — — —
Other 1 0 — 9
3 2 3 14

Compound Annual Growth %

10y 5y 3y
Sales — 76.12% 77.33%
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 133.15% (13.80%)

EPS $

Mar Jun Sep Dec Year
’26 (2.20) (8.00) — — —
’25 (1.80) (1.80) (1.60) (2.40) (7.60)
’24 (2.80) (2.80) (2.20) (2.20) (10.00)
’23 (3.00) (2.40) (2.00) (3.80) (11.20)
’22 (6.60) (3.80) (4.40) (2.20) (17.00)
’21 (4.90) (5.62) (7.67) (10.74) (29.00)
’20 (0.16) (0.14) (0.13) (19.67) (20.09)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 3 4 — — —
’25 3 3 3 3 11
’24 1 1 3 3 9
’23 1 1 1 1 4
’22 0 1 1 1 2
’21 0 0 0 1 2
’20 0 0 0 0 1
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (1) (2) — — —
’25 0 0 (1) 0 (1)
’24 (1) (1) (1) (1) (4)
’23 (1) (1) (1) (1) (3)
’22 (1) (1) (1) (1) (3)
’21 0 (1) (1) (1) (3)
’20 (1) 0 0 0 (2)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (1) (2) — — —
’25 0 0 (1) 0 (1)
’24 (1) (1) (1) (1) (4)
’23 (1) (1) (1) (1) (4)
’22 (1) (1) (1) (1) (3)
’21 (1) (1) (1) (1) (3)
’20 (1) 0 0 (1) (2)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue — — 2 1 1 2 2 4 9 11 12 +26.4% 16 24 26 +31.7%
Gross margin, % — — 21.92 (22.45) (43.18) 0.52 12.50 9.15 31.63 39.48 35.08 +17.6 pt
EBT — — (2) (2) (2) (4) (5) (3) (3) (3) (6) +6.3%
EBT margin, % — — (85.31) (268.20) (335.91) (277.89) (231.74) (77.97) (39.86) (25.33) (50.15) +60.0 pt
Net income — 0 (2) (2) (2) (4) (5) (3) (3) (3) (6) n/m
Per share, $
Per share, $ Revenue — — 0.44 0.05 5.98 10.41 7.35 14.42 26.68 29.08 26.77 +81.9%
Earnings — — (0.38) (0.14) (20.09) (29.00) (17.00) (11.20) (10.00) (7.60) (14.20) +53.4%
Cash flow — — (0.31) (0.13) (15.98) (18.48) (10.73) (11.41) (11.88) (3.34) (7.11) +40.5%
Capex — — 0.00 0.00 (2.77) (1.81) (0.34) (2.45) (1.36) (0.17) (0.30) n/m
Free cash flow — — (0.31) (0.13) (18.75) (20.28) (11.08) (13.86) (13.24) (3.51) (7.41) +41.5%
Book value — — 0.06 0.03 0.63 81.11 27.39 18.22 18.67 12.45 12.13 +116.4%
Shares, m — — 5 14 0 0 0 0 0 0 0 (30.5%)
Valuation, ×
Valuation, × P/E — — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
P/S — — 9.37 9.37 9.37 5.01 3.68 3.12 3.34 1.11 0.15 5.5
P/B — — 21.67 21.67 21.67 0.64 0.99 2.47 4.78 2.59 0.32 9.6
EV/Sales — — 8.49 8.49 8.49 (3.42) 0.58 2.59 3.25 1.09 0.32 3.7
EV/FCF — — (3.76) (3.76) (3.76) 1.75 (0.40) (2.69) (6.55) (8.57) (1.15) (3.5)
Cash, $m
Cash, $m Operating cash flow — — (2) (2) (2) (3) (3) (3) (4) (1) (3) (2.3%)
Capex — — — — 0 0 0 (1) 0 0 0 (26.3%)
Free cash flow — — (2) (2) (2) (3) (3) (4) (4) (1) (3) (1.6%)
Balance, $m
Balance, $m Working capital — — 0 0 (1) 11 7 3 3 1 (8) n/m
Net debt — — — 1 0 (13) (6) (2) (1) 0 2 n/m
Shareholders’ equity — — 0 0 0 12 8 5 6 5 5 +50.4%
Returns, %
Returns, % ROA — — (510.96) (146.29) (109.19) (44.80) (34.72) (31.09) (31.34) (27.98) (34.21) +483.0 pt
ROIC — — 0.00 0.00 (478.81) 0.00 (161.46) (72.95) (42.98) (45.90) (45.29) (45.9) pt
ROE — — (571.26) (581.85) (1,003.99) (70.91) (48.13) (49.32) (58.35) (54.69) (117.57) +516.6 pt
People
People Employees — — — — — 10 12 19 19 19 — +17.4%
Revenue/emp, $m — — 0.00 0.00 0.00 0.16 0.17 0.22 0.46 0.60 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 2 Nov 2026

NexGel, Inc. vs peers in Medical Instruments & Supplies (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
NEPH Nephros Inc. $33.6M 18.0× 20.2× +18.01% (above 0%: growing) +66.67% (above 0%: growing) −251.52% (below 0%: shrinking) 58.45% 8.91% Compare
MLSS Milestone Scientific, Inc. $27.1M — (loss-making) — (loss-making) +22.27% (above 0%: growing) n/m +66.68% (above 0%: growing) 67.24% (37.37%) Compare
RVP Retractable Technologies, Inc. $16.9M — (loss-making) 11.1× −31.07% (below 0%: shrinking) n/m +56.67% (above 0%: growing) 2.65% (71.46%) Compare
BNGO Bionano Genomics, Inc. $15.4M — (loss-making) — (loss-making) +21.36% (above 0%: growing) n/m −33.93% (below 0%: shrinking) 52.80% (88.34%) Compare
NXGL NexGel, Inc. $12.7M — (loss-making) — (loss-making) +27.81% (above 0%: growing) n/m −432.32% (below 0%: shrinking) 30.09% (67.96%)
FEMY Femasys Inc. $11.0M — (loss-making) — (loss-making) −18.93% (below 0%: shrinking) n/m +11.29% (above 0%: growing) 57.08% (1,526.79%) Compare
CUPR Cuprina Holdings (Cayman) Limited $10.4M — — — — — — — Compare
RGNT Regentis Biomaterials Ltd. $8.2M — — — — −132.79% (below 0%: shrinking) — — Compare
LUCY Innovative Eyewear, Inc. $7.2M — (loss-making) — +74.46% (above 0%: growing) n/m +9.61% (above 0%: growing) 24.00% (168.73%) Compare
Median of peers $13.2M — — +19.69% — +9.61% 54.94% (79.90%)

All 53 Medical Instruments & Supplies stocks →

Pay and ownership Proxy statement filed 24 August 2026

Ownership

Directors and executive officers, together 19.79%
Sequence LifeScience, Inc. 9.99%
Brian J. Kieser 9.99%
Asymmetry Point LP 7.64%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

NexGel, Inc. (NXGL) Latest News

27 Oct

Impact 3 · · GlobeNewswire

12 Oct

Impact 4 · · GlobeNewswire

20 Aug

Impact 4 ·

17 Aug

Impact 3 · · InvestorsHub

19 May

Impact 4 · · GlobeNewswire

15 May

Impact 4 · · The Motley Fool transcript

14 May

Impact 4 · · Moby transcript

6 May

Impact 4 · · GlobeNewswire

27 Apr

Impact 3 · · GlobeNewswire

21 Apr

Impact 4 ·
Impact 4 ·
Impact 3 · · Moby

17 Apr

Impact 4 · · GlobeNewswire

8 Apr

Impact 4 · · GuruFocus.com

31 Mar

Impact 3 · · GlobeNewswire

12 Mar

Impact 4 · · GlobeNewswire
Impact 4 · · GlobeNewswire

10 Mar

Impact 5 · · GlobeNewswire

10 Feb

Impact 4 · · GlobeNewswire

22 Dec

Impact 4 · · Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.

16 Dec

Impact 4 · · GlobeNewswire

11 Dec

Impact 4 · · GlobeNewswire

12 Nov

Impact 4 · · GuruFocus.com transcript

11 Nov

Impact 3 · · GlobeNewswire

16 Aug

Impact 3 ·

13 Aug

Impact 4 · · GuruFocus.com

12 Aug

Impact 3 · · GlobeNewswire

5 Aug

Impact 3 · · GlobeNewswire

1 Aug

Impact 3 · · GlobeNewswire

14 Jul

Impact 4 · · GlobeNewswire
stockrow.com/NXGL · Data as of Nov 2, 2026 · For information only; not investment advice. · © 2026 stockrow.com